Organon Completes Global Licensing Agreement with Sebela
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Organon announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device. Approved by the US Food and Drug Administration on February 24, 2025, MIUDELLA is the first hormone-free copper IUD to be introduced in the US in over 40 years. Indicated for the prevention of pregnancy for up to three years in females of reproductive potential, MIUDELLA is 99% effective. It features a proprietary SLIMSERTTM technology, which consists of a highly flexible frame and a fully preloaded inserter with a small, tapered insertion tube diameter of 3.7mm. MIUDELLA is anticipated to be commercially available in late 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 13.530
Low
5.00
Averages
8.50
High
12.00
Current: 13.530
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating TruBridge, Inc. (NASDAQ:TBRG) regarding its sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The law firm urges shareholders of TruBridge and Organon & Co. (NYSE:OGN), which is being sold for $14.00 per share, to be aware of their rights, as the terms may limit superior competing offers.
- Transaction Impact Analysis: The sale of Modiv Industrial, Inc. (NYSE:MDV) to Global Net Lease, Inc. will result in Modiv shareholders owning approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no out-of-pocket costs for investors, aiming to protect their rights and pursue higher transaction compensation.
See More
Jefferies Reports Doubling of Profit in Q2 Amid Strong Investment Banking Trends
- Profit Surge: Jefferies reported a profit of $226.2 million in Q2, translating to $1.02 per share, a significant increase from $88 million or $0.40 per share a year ago, indicating robust performance in investment banking.
- Advisory Revenue Boom: Advisory revenue surged 47% to a record $674.1 million, while investment banking net revenues jumped 57.5% year-over-year to $1.21 billion, reflecting strong demand for M&A advisory services in the current market.
- Equity Market Activity: Equity underwriting revenue exceeded $370.7 million in the quarter, more than tripling year-over-year, with Jefferies acting as joint global coordinator on Galderma's $6.3 billion share sale, marking the largest sponsor-backed block trade in history.
- Trading Revenue Growth: Jefferies' capital markets business posted $799.3 million in revenue, up 13.5% from last year, with equities trading revenue rising 14% to a record $600.8 million, highlighting a trend of investors adjusting portfolios amid market volatility.
See More
Organon and Henlius Launch Biosimilars in Canada
- Biosimilar Launch: Organon Canada and Shanghai Henlius Biotech announced the Canadian launch of Bildyos and Tuzemty, biosimilars to Prolia and Xgeva, respectively, expanding treatment availability across all approved indications.
- Patient Benefits: The launch increases access to denosumab-based therapies for osteoporosis and cancer-related bone conditions, potentially benefiting 2.3 million Canadians, particularly women, by enhancing their treatment options.
- Market Strategy Enhancement: By expanding its biosimilars portfolio, Organon strengthens its competitive position in the Canadian market, reinforcing its commitment to innovation and responsiveness to patient needs in the biopharmaceutical sector.
- Healthcare System Commitment: Dominic Bégin, president of Organon Canada, emphasized that this development not only improves treatment accessibility but also supports the strengthening of the healthcare system, reflecting the company's ongoing dedication to patient care.
See More
Organon Launches New Biosimilars in Canada
- Portfolio Expansion: Organon, in collaboration with Shanghai Henlius Biotech, has launched BILDYOS® and TUZEMTY® biosimilars in Canada, expanding its biosimilars portfolio to eight products across five therapeutic areas, significantly enhancing treatment options for patients nationwide.
- Meeting Market Demand: These denosumab products are used to treat osteoporosis and bone events associated with cancer, addressing the urgent needs of 2.3 million Canadian women, which is expected to improve patient quality of life and alleviate the burden on the healthcare system.
- Deepening Strategic Collaboration: The launch of these products marks a significant step in the partnership between Organon and Henlius, as both companies are committed to providing new treatment options and reinforcing long-term access to biosimilars in the market.
- Focus on Women's Health: By introducing new approved denosumab therapies, Organon strengthens its leadership in women's health, aiming to enhance the resilience of the healthcare system through a patient-centered approach, thereby aiding clinicians and patients in navigating osteoporosis treatment options more flexibly.
See More
Investigation Alerts for Multiple Company Mergers
- Apogee Acquisition: Apogee Therapeutics is set to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion, with investigations focusing on whether the Apogee Board breached fiduciary duties by failing to conduct a fair process.
- Roku Merger Deal: Roku will be acquired by Fox Corporation for $160.00 per share, with an enterprise value of around $22 billion, as investigations examine whether the Roku Board ensured fair value for shareholders in the transaction.
- TruBridge Acquisition Inquiry: TruBridge is to be acquired by Inventurus Knowledge Solutions for $26.25 per share in cash, with investigations looking into whether the TruBridge Board failed to conduct a fair process, potentially harming shareholder interests.
- Organon Merger Investigation: Organon will be acquired by Sun Pharmaceutical for $14.00 per share in an all-cash deal, with an enterprise valuation of $11.75 billion, as investigations assess whether the Organon Board fulfilled its fiduciary duties to ensure fair value for shareholders.
See More
Organon Completes Global Licensing Agreement for MIUDELLA
- Licensing Agreement: Organon has completed a global licensing agreement with Sebela Pharmaceuticals, granting exclusive rights to MIUDELLA®, a hormone-free copper IUD expected to launch by late 2026, thereby expanding contraceptive options for women.
- Clinical Trial Results: MIUDELLA demonstrated a 99% efficacy and a 98.8% placement success rate in three clinical trials involving 1,904 women, indicating its strong potential in the contraceptive market to meet women's needs for long-acting reversible birth control.
- Strategic Market Impact: As the first hormone-free copper IUD introduced in the U.S. in over 40 years, MIUDELLA's launch, supported by a REMS program to ensure proper training for healthcare providers, enhances Organon's competitive position in the women's health sector by mitigating risks associated with improper insertion.
- Company Vision: Joe Morrissey, CEO of Organon, emphasized that this agreement strengthens the company's capabilities in contraception, aiming to provide more options that meet women's needs, reflecting a strategic commitment to the global women's health market.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating TruBridge, Inc. (NASDAQ:TBRG) regarding its sale to Inventurus Knowledge Solutions, Inc. for $26.25 per share, potentially infringing on shareholder rights.
- Shareholder Rights Protection: The law firm urges shareholders of TruBridge and Organon & Co. (NYSE:OGN), which is being sold for $14.00 per share, to be aware of their rights, as the terms may limit superior competing offers.
- Transaction Impact Analysis: The sale of Modiv Industrial, Inc. (NYSE:MDV) to Global Net Lease, Inc. will result in Modiv shareholders owning approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Service Commitment: Halper Sadeh LLC offers legal services on a contingency fee basis, ensuring no out-of-pocket costs for investors, aiming to protect their rights and pursue higher transaction compensation.
See More
Jefferies Reports Doubling of Profit in Q2 Amid Strong Investment Banking Trends
- Profit Surge: Jefferies reported a profit of $226.2 million in Q2, translating to $1.02 per share, a significant increase from $88 million or $0.40 per share a year ago, indicating robust performance in investment banking.
- Advisory Revenue Boom: Advisory revenue surged 47% to a record $674.1 million, while investment banking net revenues jumped 57.5% year-over-year to $1.21 billion, reflecting strong demand for M&A advisory services in the current market.
- Equity Market Activity: Equity underwriting revenue exceeded $370.7 million in the quarter, more than tripling year-over-year, with Jefferies acting as joint global coordinator on Galderma's $6.3 billion share sale, marking the largest sponsor-backed block trade in history.
- Trading Revenue Growth: Jefferies' capital markets business posted $799.3 million in revenue, up 13.5% from last year, with equities trading revenue rising 14% to a record $600.8 million, highlighting a trend of investors adjusting portfolios amid market volatility.
See More
Organon and Henlius Launch Biosimilars in Canada
- Biosimilar Launch: Organon Canada and Shanghai Henlius Biotech announced the Canadian launch of Bildyos and Tuzemty, biosimilars to Prolia and Xgeva, respectively, expanding treatment availability across all approved indications.
- Patient Benefits: The launch increases access to denosumab-based therapies for osteoporosis and cancer-related bone conditions, potentially benefiting 2.3 million Canadians, particularly women, by enhancing their treatment options.
- Market Strategy Enhancement: By expanding its biosimilars portfolio, Organon strengthens its competitive position in the Canadian market, reinforcing its commitment to innovation and responsiveness to patient needs in the biopharmaceutical sector.
- Healthcare System Commitment: Dominic Bégin, president of Organon Canada, emphasized that this development not only improves treatment accessibility but also supports the strengthening of the healthcare system, reflecting the company's ongoing dedication to patient care.
See More
Organon Launches New Biosimilars in Canada
- Portfolio Expansion: Organon, in collaboration with Shanghai Henlius Biotech, has launched BILDYOS® and TUZEMTY® biosimilars in Canada, expanding its biosimilars portfolio to eight products across five therapeutic areas, significantly enhancing treatment options for patients nationwide.
- Meeting Market Demand: These denosumab products are used to treat osteoporosis and bone events associated with cancer, addressing the urgent needs of 2.3 million Canadian women, which is expected to improve patient quality of life and alleviate the burden on the healthcare system.
- Deepening Strategic Collaboration: The launch of these products marks a significant step in the partnership between Organon and Henlius, as both companies are committed to providing new treatment options and reinforcing long-term access to biosimilars in the market.
- Focus on Women's Health: By introducing new approved denosumab therapies, Organon strengthens its leadership in women's health, aiming to enhance the resilience of the healthcare system through a patient-centered approach, thereby aiding clinicians and patients in navigating osteoporosis treatment options more flexibly.
See More
Investigation Alerts for Multiple Company Mergers
- Apogee Acquisition: Apogee Therapeutics is set to be acquired by AbbVie for $135.11 per share in cash, valuing the company at approximately $10.9 billion, with investigations focusing on whether the Apogee Board breached fiduciary duties by failing to conduct a fair process.
- Roku Merger Deal: Roku will be acquired by Fox Corporation for $160.00 per share, with an enterprise value of around $22 billion, as investigations examine whether the Roku Board ensured fair value for shareholders in the transaction.
- TruBridge Acquisition Inquiry: TruBridge is to be acquired by Inventurus Knowledge Solutions for $26.25 per share in cash, with investigations looking into whether the TruBridge Board failed to conduct a fair process, potentially harming shareholder interests.
- Organon Merger Investigation: Organon will be acquired by Sun Pharmaceutical for $14.00 per share in an all-cash deal, with an enterprise valuation of $11.75 billion, as investigations assess whether the Organon Board fulfilled its fiduciary duties to ensure fair value for shareholders.
See More
Organon Completes Global Licensing Agreement for MIUDELLA
- Licensing Agreement: Organon has completed a global licensing agreement with Sebela Pharmaceuticals, granting exclusive rights to MIUDELLA®, a hormone-free copper IUD expected to launch by late 2026, thereby expanding contraceptive options for women.
- Clinical Trial Results: MIUDELLA demonstrated a 99% efficacy and a 98.8% placement success rate in three clinical trials involving 1,904 women, indicating its strong potential in the contraceptive market to meet women's needs for long-acting reversible birth control.
- Strategic Market Impact: As the first hormone-free copper IUD introduced in the U.S. in over 40 years, MIUDELLA's launch, supported by a REMS program to ensure proper training for healthcare providers, enhances Organon's competitive position in the women's health sector by mitigating risks associated with improper insertion.
- Company Vision: Joe Morrissey, CEO of Organon, emphasized that this agreement strengthens the company's capabilities in contraception, aiming to provide more options that meet women's needs, reflecting a strategic commitment to the global women's health market.
See More
